{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:27:11Z","timestamp":1768465631436,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T00:00:00Z","timestamp":1402963200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1755-8794-7-35","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T08:48:30Z","timestamp":1402994910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone"],"prefix":"10.1186","volume":"7","author":[{"given":"Lars","family":"Verschuren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Y","family":"Wielinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijana","family":"Radonjic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanita","family":"Salic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kleemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"van Ommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teake","family":"Kooistra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,17]]},"reference":[{"issue":"2","key":"490_CR1","first-page":"174","volume":"39","author":"KI Khalaf","year":"2012","unstructured":"Khalaf KI, Taegtmeyer H: After avandia: the use of antidiabetic drugs in patients with heart failure. Tex Heart Inst J. 2012, 39 (2): 174-178.","journal-title":"Tex Heart Inst J"},{"key":"490_CR2","doi-asserted-by":"publisher","first-page":"d1309","DOI":"10.1136\/bmj.d1309","volume":"342","author":"YK Loke","year":"2011","unstructured":"Loke YK, Kwok CS, Singh S: Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011, 342: d1309.","journal-title":"BMJ"},{"key":"490_CR3","unstructured":"US FDA: Avandia (rosiglitazone): REMS \u2013 risk of cardiovascular events [online]. Available from URL: http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm226994.htm [Accessed 2010 Dec 6]"},{"issue":"19","key":"490_CR4","doi-asserted-by":"publisher","first-page":"8260","DOI":"10.1021\/jm301204r","volume":"55","author":"BR Hoffmann","year":"2012","unstructured":"Hoffmann BR, El-Mansy MF, Sem DS, Greene AS: Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity. J Med Chem. 2012, 55 (19): 8260-8271.","journal-title":"J Med Chem"},{"issue":"9541","key":"490_CR5","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","volume":"368","author":"HC Gerstein","year":"2006","unstructured":"Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR, DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006, 368 (9541): 1096-1105.","journal-title":"Lancet"},{"issue":"2","key":"490_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.toxlet.2010.12.012","volume":"201","author":"I Mikaelian","year":"2011","unstructured":"Mikaelian I, Buness A, Hirkaler G, Fernandes R, Coluccio D, Geng W, Visalli T, Bachynsky MO, Berkofsky-Fessler W, Kanwal C, Hilton H, Nicklaus R, Hoflack JC, Dunn M, Sanders M, Giron M, Boyle BW, Singer T, Dick LS: Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone. Toxicol Lett. 2011, 201 (2): 110-115.","journal-title":"Toxicol Lett"},{"issue":"22","key":"490_CR7","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995, 270 (22): 12953-12956.","journal-title":"J Biol Chem"},{"issue":"4","key":"490_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1517\/14740338.2012.691963","volume":"11","author":"J Kung","year":"2012","unstructured":"Kung J, Henry RR: Thiazolidinedione safety. Expert Opin Drug Saf. 2012, 11 (4): 565-579.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"490_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nrg2983","volume":"12","author":"EE Creemers","year":"2011","unstructured":"Creemers EE, Wilde AA, Pinto YM: Heart failure: advances through genomics. Nat Rev Genet. 2011, 12 (5): 357-362.","journal-title":"Nat Rev Genet"},{"issue":"4","key":"490_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/01.RES.0000179226.34112.6d","volume":"97","author":"SZ Duan","year":"2005","unstructured":"Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM: Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res. 2005, 97 (4): 372-379.","journal-title":"Circ Res"},{"issue":"2","key":"490_CR11","doi-asserted-by":"publisher","first-page":"e56122","DOI":"10.1371\/journal.pone.0056122","volume":"8","author":"M Radonjic","year":"2013","unstructured":"Radonjic M, Wielinga PY, Wopereis S, Kelder T, Goelela VS, Verschuren L, Toet K, van Duyvenvoorde W, van der Werff van der Vat B, Stroeve JH, Cnubben N, Kooistra T, van Ommen B, Kleemann R: Differential effects of drug interventions and dietary lifestyle in developing type 2 diabetes and complications: a systems biology analysis in LDLr-\/- mice. PLoS One. 2013, 8 (2): e56122.","journal-title":"PLoS One"},{"issue":"1","key":"490_CR12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.ATV.0000148866.29829.19","volume":"25","author":"L Verschuren","year":"2005","unstructured":"Verschuren L, Kleemann R, Offerman EH, Szalai AJ, Emeis SJ, Princen HM, Kooistra T: Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol. 2005, 25 (1): 161-167.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"490_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/FPC.0b013e328359d274","volume":"22","author":"L Verschuren","year":"2012","unstructured":"Verschuren L, Radonjic M, Wielinga PY, Kelder T, Kooistra T, van Ommen B, Kleemann R: Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy. Pharmacogenet Genomics. 2012, 22 (12): 837-845.","journal-title":"Pharmacogenet Genomics"},{"issue":"13","key":"490_CR14","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/bioinformatics\/btn224","volume":"24","author":"P Du","year":"2008","unstructured":"Du P, Kibbe WA, Lin SM: lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008, 24 (13): 1547-1548.","journal-title":"Bioinformatics"},{"key":"490_CR15","volume-title":"Stat Appl Genet Mol Biol","author":"GK Smyth","year":"2004","unstructured":"Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004, 3: Article3"},{"issue":"24","key":"490_CR16","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007, 356 (24): 2457-2471.","journal-title":"N Engl J Med"},{"issue":"17","key":"490_CR17","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.jacc.2010.02.014","volume":"55","author":"S Kaul","year":"2010","unstructured":"Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH: American Heart Association, American College Of Cardiology Foundation: Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. J Am Coll Cardiol. 2010, 55 (17): 1885-1894.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"490_CR18","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.2215\/CJN.09291010","volume":"6","author":"JM Lachin","year":"2011","unstructured":"Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Holman RR, Kahn SE, ADOPT Study Group: Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol. 2011, 6 (5): 1032-1040.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"490_CR19","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1007\/s00125-010-1804-y","volume":"53","author":"PD Home","year":"2010","unstructured":"Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G, ADOPT Study Group: RECORD Steering Committee: Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia. 2010, 53 (9): 1838-1845.","journal-title":"Diabetologia"},{"issue":"11","key":"490_CR20","doi-asserted-by":"publisher","first-page":"e27126","DOI":"10.1371\/journal.pone.0027126","volume":"6","author":"V Kus","year":"2011","unstructured":"Kus V, Flachs P, Kuda O, Bardova K, Janovska P, Svobodova M, Jilkova ZM, Rossmeisl M, Wang-Sattler R, Yu Z, Illig T, Kopecky J: Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. PLoS One. 2011, 6 (11): e27126.","journal-title":"PLoS One"},{"issue":"4","key":"490_CR21","doi-asserted-by":"publisher","first-page":"F1141","DOI":"10.1152\/ajprenal.00288.2005","volume":"292","author":"S Ohga","year":"2007","unstructured":"Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, Wada J, Shikata Y, Makino H: Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol. 2007, 292 (4): F1141-F1150.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"490_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","volume":"128","author":"BC Bernardo","year":"2010","unstructured":"Bernardo BC, Weeks KL, Pretorius L, McMullen JR: Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010, 128 (1): 191-227.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"490_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1365-2362.2004.01348.x","volume":"34","author":"AM Grandi","year":"2004","unstructured":"Grandi AM, Laurita E, Selva E, Piantanida E, Imperiale D, Giovanella L, Guasti L, Venco A: Natriuretic peptides as markers of preclinical cardiac disease in obesity. Eur J Clin Invest. 2004, 34 (5): 342-348.","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"490_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00592-007-0256-4","volume":"44","author":"Y Turkmen Kemal","year":"2007","unstructured":"Turkmen Kemal Y, Guvener Demirag N, Yildirir A, Atar A, Dogruk Unal A, Biyiklioglu Z: Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus. Acta Diabetol. 2007, 44 (3): 149-156.","journal-title":"Acta Diabetol"},{"issue":"8","key":"490_CR25","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1210\/jc.2002-021765","volume":"88","author":"S Ogawa","year":"2003","unstructured":"Ogawa S, Takeuchi K, Ito S: Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab. 2003, 88 (8): 3993-3996.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"490_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.cardiores.2007.06.027","volume":"76","author":"G Ding","year":"2007","unstructured":"Ding G, Fu M, Qin Q, Lewis W, Kim HW, Fukai T, Bacanamwo M, Chen YE, Schneider MD, Mangelsdorf DJ, Evans RM, Yang Q: Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc Res. 2007, 76 (2): 269-279.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"490_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.7150\/ijbs.3.385","volume":"3","author":"BC Henderson","year":"2007","unstructured":"Henderson BC, Sen U, Reynolds C, Moshal KS, Ovechkin A, Tyagi N, Kartha GK, Rodriguez WE, Tyagi SC: Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone. Int J Biol Sci. 2007, 3 (6): 385-392.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"490_CR28","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1172\/JCI30335","volume":"117","author":"NH Son","year":"2007","unstructured":"Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ: Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 2007, 117 (10): 2791-2801.","journal-title":"J Clin Invest"},{"issue":"6","key":"490_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cmet.2009.05.005","volume":"9","author":"J Krishnan","year":"2009","unstructured":"Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C, Tokarska-Schlattner M, Aasum E, Bogdanova A, Perriard E, Perriard JC, Larsen T, Pedrazzini T, Krek W: Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab. 2009, 9 (6): 512-524.","journal-title":"Cell Metab"},{"issue":"1","key":"490_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC: Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010, 90 (1): 207-258.","journal-title":"Physiol Rev"},{"issue":"1","key":"490_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/cvr\/cvn001","volume":"78","author":"PJ Smeets","year":"2008","unstructured":"Smeets PJ, Teunissen BE, Willemsen PH, van Nieuwenhoven FA, Brouns AE, Janssen BJ, Cleutjens JP, Staels B, van der Vusse GJ, van Bilsen M: Cardiac hypertrophy is enhanced in PPAR alpha-\/- mice in response to chronic pressure overload. Cardiovasc Res. 2008, 78 (1): 79-89.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"490_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cmet.2005.03.002","volume":"1","author":"Z Arany","year":"2005","unstructured":"Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu PH, Rybkin II, Shelton JM, Manieri M, Cinti S, Schoen FJ, Bassel-Duby R, Rosenzweig A, Ingwall JS, Spiegelman BM: Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 2005, 1 (4): 259-271.","journal-title":"Cell Metab"},{"issue":"14","key":"490_CR33","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.111.075978","volume":"126","author":"L He","year":"2012","unstructured":"He L, Kim T, Long Q, Liu J, Wang P, Zhou Y, Ding Y, Prasain J, Wood PA, Yang Q: Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation. 2012, 126 (14): 1705-1716.","journal-title":"Circulation"},{"issue":"4","key":"490_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2174\/1381612053382061","volume":"11","author":"A Grynberg","year":"2005","unstructured":"Grynberg A: Effectors of fatty acid oxidation reduction: promising new anti-ischaemic agents. Curr Pharm Des. 2005, 11 (4): 489-509.","journal-title":"Curr Pharm Des"},{"issue":"12","key":"490_CR35","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/labinvest.2009.86","volume":"89","author":"KB Cox","year":"2009","unstructured":"Cox KB, Liu J, Tian L, Barnes S, Yang Q, Wood PA: Cardiac hypertrophy in mice with long-chain acyl-CoA dehydrogenase or very long-chain acyl-CoA dehydrogenase deficiency. Lab Invest. 2009, 89 (12): 1348-1354.","journal-title":"Lab Invest"},{"issue":"1","key":"490_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1152\/physiolgenomics.00127.2009","volume":"41","author":"LM Sanderson","year":"2010","unstructured":"Sanderson LM, Boekschoten MV, Desvergne B, Muller M, Kersten S: Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta\/delta in regulation of gene expression in mouse liver. Physiol Genomics. 2010, 41 (1): 42-52.","journal-title":"Physiol Genomics"},{"key":"490_CR37","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/ncomms3019","volume":"4","author":"A Planavila","year":"2013","unstructured":"Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, Gabrielli LA, Sitges M, Giralt M, van Bilsen M, Villarroya F: Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013, 4: 2019.","journal-title":"Nat Commun"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1755-8794-7-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1755-8794-7-35\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1755-8794-7-35","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T12:08:08Z","timestamp":1565525288000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/1755-8794-7-35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,17]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1186\/1755-8794-7-35","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,17]]},"article-number":"35"}}